Medicis (MRX) and ReVance Therapeutics, Inc. Announce Agreement for Development of Next-Gen Neurotoxin; Revance to Receive $10M and Additional Milestone Payments of $94M
7/29/2009 7:34:06 AM
More...
|
ReVance Therapeutics, Inc. Levers Up with $8 Million Financing
11/18/2008 8:11:52 AM
More...
|
ReVance Therapeutics, Inc. Announces Additional $8M Series C Expansion
5/12/2008 10:13:26 AM
More...
|
Medicis (MRX) and ReVance Therapeutics, Inc. Announce Strategic Collaboration
12/12/2007 8:52:34 AM
More...
|
ReVance Therapeutics, Inc. Announces Initiation Of Phase Ib Clinical Trial Of Topically Applied Botulinum Toxin Type A Gel For The Treatment Of Facial Aesthetics
11/9/2006 11:37:49 AM
More...
|
ReVance Therapeutics, Inc. Announces Management Additions; Company Strengthens Clinical, Regulatory And R&D Capabilities
10/19/2005 5:09:19 PM
More...
|